NCT04196530 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
Clinical Trials
7 trialsNCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT02410512 2022-04-01
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT03835949 2022-04-01
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Tracon Pharmaceuticals Inc.
Phase 1 Unknown
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01688206 2018-10-05
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed